TRH and chronic kidney disease: While there is no head-to-head randomized comparison between finerenone and steroidal MRAs in patients with CKD, an indirect post hoc analysis comparing 624 patients from the FIDELITY-TRH subgroup with 295 patients from the AMBER trial reported a markedly lower incidence of hyperkalemia with finerenone (48).